The Food and Drug Administration has approved a second blood test for colorectal cancer screening, giving adults who avoid colonoscopy and stool tests another option and giving clinicians another conversation to have about what that option does and does not find.
Freenome's SimpleScreen CRC, approved July 27, joins Guardant Health's Shield, approved in 2024. Both are indicated for adults aged 45 and older at average risk who have been referred for screening. MedTech Dive reported that Abbott will exclusively market SimpleScreen in the United States starting this fall, alongside the Cologuard stool test it acquired through its purchase of Exact Sciences earlier this year.
